Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.

Registrati

Quotazioni in diretta

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/26/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

08/12/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Xinsheng Liao

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni BeiGene (NASDAQ:BGNE)
Storico
Da Feb 2025 a Mar 2025

Clicca qui per i Grafici di BeiGene

Grafico Azioni BeiGene (NASDAQ:BGNE)
Storico
Da Mar 2024 a Mar 2025

Clicca qui per i Grafici di BeiGene

Notizie BeiGene Ltd - BGNE

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Mercoledì 8 Gennaio 2025 (2 mesi fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Martedì 7 Gennaio 2025 (2 mesi fa) • Edgar (US Regulatory)

TEVIMBRA erhält US-Marktzulassung für die Erstlinienbehandlung von Magen- und GEJ-Tumoren in Kombination mit Chemotherapie
Sabatp 28 Dicembre 2024 (2 mesi fa) • Business Wire

Le TEVIMBRA est approuvé aux États-Unis pour le traitement de première intention des cancers gastrique et de la jonction gastro-œsophagienne en association avec une chimiothérapie
Venerdì 27 Dicembre 2024 (2 mesi fa) • Business Wire

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
Venerdì 27 Dicembre 2024 (2 mesi fa) • Business Wire

BeiGene ändert am 2. Januar Nasdaq Tickersymbol in “ONC"; auf der 43. Annual J.P. Morgan Healthcare Conference präsent
Lunedì 23 Dicembre 2024 (2 mesi fa) • Business Wire

ベイジーン、1月2日にナスダックのティッカーシンボルを「ONC」に変更、第43回J.P. モルガン・ヘルスケア・カンファレンスでプレゼンテーションを予定
Lunedì 23 Dicembre 2024 (2 mesi fa) • Business Wire

BeiGene將於1月2日將那斯達克股票代號更改為「ONC」，並將出席第43屆J.P. Morgan醫療健康年會
Lunedì 23 Dicembre 2024 (2 mesi fa) • Business Wire

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
Lunedì 23 Dicembre 2024 (2 mesi fa) • Business Wire

BeiGene gibt globale Lizenzvereinbarung für MAT2A-Inhibitor bekannt
Venerdì 13 Dicembre 2024 (3 mesi fa) • Business Wire

BeiGene annonce un accord de licence mondial pour l’inhibiteur MAT2A
Venerdì 13 Dicembre 2024 (3 mesi fa) • Business Wire

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
Venerdì 13 Dicembre 2024 (3 mesi fa) • Business Wire

Più BeiGene Ltd Articoli Notizie

Intesa Sanpaolo

ST Microelectronics

Banca Monte Dei Paschi D...

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea